LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in bio-analytical testing, and a key player in the European clinical diagnostics market, announces the acquisition of Labo Van Poucke (“LVP”), a leading laboratory performing human medical testing covering all branches of clinical biology.
LVP was founded in 1969 and has been a 100% family-owned business ever since. LVP performs almost all medical analyses commonly requested by general practitioners and specialists. The Company offers testing for hematology, serology, chemistry, immunology, microbiology and molecular biology. Furthermore, LVP also offers analysis of drinking water as well as veterinary analysis. LVP offers a wide range of state-of-the-art medical testing services, while delivering industry-leading turn-around-times as a result of their state-of-the-art technology and equipment.
LVP is licensed by the Belgian Scientific Institute of Public Health (WIV-ISP) for clinical pathology testing. The Company is also licensed by the Belgian Federal Agency for Nuclear Control (FANC) for isotopic tests. LVP has been accredited by the Belgian Accreditation Body (BELAC) since 1997, and operates in compliance with the ISO 15189 standard for medical laboratories. LVP employs 34 staff and generated revenues close to EUR 5m in 2017.
This acquisition provides Eurofins an entry platform into the clinical testing market in Belgium and a license to operate and sell its specialties in this market. LVP’s broad range of testing services, combined with LifeCodexx’s and Genoma’s clinical genetics capabilities acquired in 2017, in particular in non-invasive prenatal testing (NIPT), as well as Biomnis’ broad portfolio of clinical diagnostic solutions, significantly strengthens Eurofins’ growing footprint in the specialty clinical diagnostics testing market in Europe.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are extremely pleased to welcome Labo Van Poucke, a family-owned clinical diagnostics specialist, to Eurofins’ family of businesses. This acquisition provides Eurofins with a valuable entry into the Belgian clinical diagnostics market; in return LVP will gain access to the full range of services and capabilities of the Eurofins Group, which will significantly increase LVP’s testing portfolio for the benefit of medical practitioners and their patients”.
For more information, please visit www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 400 laboratories across 42 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.